TY - JOUR
T1 - Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study
AU - MASK study group
AU - Bédard, Annabelle
AU - Basagaña, Xavier
AU - Anto, Josep M.
AU - Garcia-Aymerich, Judith
AU - Devillier, Philippe
AU - Arnavielhe, Sylvie
AU - Bedbrook, Anna
AU - Onorato, Gabrielle L.
AU - Czarlewski, Wienczyslawa
AU - Murray, Ruth
AU - Almeida, Rute
AU - Fonseca, Joao
AU - Costa, Elisio
AU - Malva, Joao
AU - Morais-Almeida, Mario
AU - Pereira, Ana Margarida
AU - Todo-Bom, Ana
AU - Menditto, Enrica
AU - Stellato, Cristiana
AU - Ventura, Maria Teresa
AU - Cruz, Alvaro A.
AU - Stelmach, Rafaël
AU - da Silva, Jane
AU - Larenas-Linnemann, D. sirée
AU - Fuentes-Pérez, José M.
AU - Huerta-Villalobos, Yunuen R.
AU - Emuzyte, Regina
AU - Kvedariene, Violeta
AU - Valiulis, Arunas
AU - Kuna, Piotr
AU - Samolinski, Boleslaw
AU - Klimek, Ludger
AU - Mösges, Ralph
AU - Pfaar, Oliver
AU - Shamai, Sara
AU - Annesi-Maesano, Isabelle
AU - Bosse, Isabelle
AU - Demoly, Pascal
AU - Fontaine, Jean-François
AU - Cardona, Vicky
AU - Mullol, Joaquim
AU - Valero, Antonio
AU - Roller-Wirnsberger, Regina E.
AU - Tomazic, Peter Valentin
AU - Chavannes, Niels H.
AU - Fokkens, Wytske J.
AU - Reitsma, Sietze
AU - Bewick, Mike
AU - Ryan, Dermot
AU - Hellings, Peter W.
PY - 2019/7
Y1 - 2019/7
N2 - Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR)control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores)was used to collect the data of daily visual analogue scale (VAS)scores for (1)overall allergic symptoms; (2)nasal, ocular, and asthma symptoms; (3)work; and (4)medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter)customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H 1 -antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid–treated days), or multiple (worst control)treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H 1 -antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS)on a mobile phone had the potential to answer questions previously thought infeasible.
AB - Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR)control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores)was used to collect the data of daily visual analogue scale (VAS)scores for (1)overall allergic symptoms; (2)nasal, ocular, and asthma symptoms; (3)work; and (4)medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter)customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H 1 -antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid–treated days), or multiple (worst control)treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H 1 -antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS)on a mobile phone had the potential to answer questions previously thought infeasible.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85064769159&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30951790
U2 - https://doi.org/10.1016/j.jaci.2019.01.053
DO - https://doi.org/10.1016/j.jaci.2019.01.053
M3 - Article
C2 - 30951790
SN - 0091-6749
VL - 144
SP - 135
EP - 143
JO - Journal of allergy and clinical immunology
JF - Journal of allergy and clinical immunology
IS - 1
ER -